Pharsight

Alphagan P generic

Alphagan P is an eye drop medicine owned by Allergan. The main component of this drug is brimonidine tartrate. It was authorized for market use on 16th March, 2001. The drug is available in a solution or drops form, intended for ophthalmic use.

When will Alphagan P generic be available?

The generic version of Alphagan P is expected to be released after 2nd March, 2024. The last patent, US8858961*PED, expires on this date, allowing the opportunity for manufacturers to produce Alphagan P generic.

Alphagan P uses

Alphagan P is used to reduce pressure within the eye. It contains the active ingredient, brimonidine tartrate, which works as an alpha-2-adrenergic agonist. This helps in decreasing the amount of fluid within the eye, thus effectively lowering the eye pressure.

Alphagan P patent expiration

Alphagan P holds a total of 8 patents, with 7 already expired. The last one, US8858961*PED, is set to expire on 2nd March, 2024. Post this date, there is the possibility of Alphagan P generic being released. Below are the details of the patent:

Alphagan P dosage

Want to ask something?